InsidersTradesSigma
Track the 한올바이오파마 share price and the full insider trade history of the company, a listed equity based in South Korea. Shares trade on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 한올바이오파마 has published 6 insider filings. Market capitalisation: €2,311.5bn. The latest transaction was disclosed on 2 July 2026 (Mixed). Among the most active insiders: 국민연금공단. All data is openly available.
6
Insider Decl.
n/a
Thresholds
€19m
4 ops.
Buy Volume
n/a
n/a
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,861 of 29,063 companies
34.4
score / 100
Value33
Quality35
FCF yld-0.6%
Earn yld-0.2%
EV/EBITDA·
ROE-16%
Gross mgn52%
Net mgn-3.6%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 July 2026
Declarations6 total
6 of 6 declarations
关于 한올바이오파마
Hanall Biopharma 是一家生物制药公司，专注于开发自身免疫疾病和眼科疾病的创新疗法。该公司在 XKRX 市场上市。